Skip to main content

Table 2 Gait Assessment

From: Rivastigmine improves dual-task gait velocity in patients with Alzheimer’s disease

  Baseline 12 weeks p-value (12 weeks vs. baseline)
Rivastigmine 0 mg 18 mg/day  
Single-task gait trials
 Normal gait (mean, SD)
  velocity (m/min) 59.21 (12.21) 59.82 (11.46) 0.733
  stride length (cm) 50.11 (7.52) 51.68 (7.27) 0.111
  cadence (steps/min) 117.69 (12.26) 115.55 (13.26) 0.412
 Fast gait (mean, SD)
  velocity (m/min) 70.33 (16.06) 69.44 (12.62) 0.691
  stride length (cm) 54.64 (8.58) 55.5 (7.95) 0.367
  cadence (steps/min) 127.69 (13.37) 125.11 (13.17) 0.406
Dual-task gait trials
 Counting backward by 7 s
  velocity (m/min) 40.59 (13.59) 46.88 (12.73) 0.025*
  stride length (cm) 46 (9.29) 46.37 (6.61) 0.716
  cadence (steps/min) 89.37 (24.64) 99.35 (18.02) 0.048*
 Naming animals
  velocity (m/min) 37.06 (15.57) 42.03 (14.02) 0.036*
  stride length (cm) 46.25 (9.24) 47.55 (7.46) 0.199
  cadence (steps/min) 80.46 (27.15) 88.76 (23.42) 0.076
  1. Paired sample t-test: *p < 0.05
  2. SD Standard deviation